Lung Cancer

Alexander Watson, MD, DPhil, FRCPC, details findings showing oncogene overlap is adequately applied to NGS-based tissue sampling by decreasing frequency and increasing copy number gain.

This segment discusses the importance of biomarker testing in lung cancer, challenges in implementation such as tissue adequacy and result delays, and strategies to enhance testing in both academic and community settings through local champions and education.

This segment explores the role of biomarker testing in optimizing outcomes for non-small cell lung cancer (NSCLC), highlighting challenges in early-stage testing, the importance of multidisciplinary collaboration, and recent advances like the LAURA trial that emphasize the need for comprehensive biomarker assessment.

This video segment discusses defining resectability for Stage III lung cancer, the importance of a multidisciplinary approach to decision-making involving surgical, medical, radiation oncology, and diagnostic teams, and the role of patient engagement in tailoring treatment plans to individual priorities, risks, and physiological suitability.

The European Commission approved first-line amivantamab plus lazertinib for EGFR-mutated advanced non–small cell lung cancer.

The second-line setting for HER2-mutated NSCLC is shifting with TKIs looking to demonstrate efficacy and T-DXd under examination in the frontline now.

Sotorasib doublet gets approved for KRAS G12C–mutated CRC, acalabrutinib triplet is cleared for previously untreated MCL, and more from OncLive.

Ewa Kalinka, MD, PhD, discusses interim phase 2 data with frontline BMS-986012 plus nivolumab and chemotherapy in extensive-stage small cell lung cancer.

Limertinib was approved in China for locally advanced or metastatic non–small cell lung cancer harboring an EGFR T790M mutation.

Alison Schram, MD, details data from the eNRGy study that supported the FDA approval of zenocutuzumab in NRG1 fusion–positive NSCLC and pancreatic adenocarcinoma.

Suresh Senan, MRCP, FRCR, PhD, details how the FDA approval of durvalumab has changed care for patients with limited-stage small cell lung cancer.

Benjamin P. Levy, MD, shares insight on current challenges with TROP2-directed antibody-drug conjugates in NSCLC.

Savolitinib has received full NMPA approval for locally advanced/metastatic non–small cell lung cancer with MET exon 14 skipping alterations.

Nicolas Girard, MD, discusses differences in the mechanisms of action for HER2-directed TKIs vs antibody-drug conjugates in HER2-mutant NSCLC.

The BLA for Dato-DXd in locally advanced or metastatic EGFR-mutated NSCLC has been accepted and granted priority review by the FDA.

Sunvozertinib gets priority review in EGFR-mutated NSCLC, iparomlimab/tuvonralimab combination elicits responses in cervical cancer, and more.

Data from a phase 2 trial demonstrated that abenacianine is a safe investigational tumor-targeted fluorescent imaging agent for tumors in the lung.

BBO-8520 has received FDA fast track designation in previously treated KRAS G12C–mutated metastatic non–small cell lung cancer.

The FDA has granted priority review to sunvozertinib for advanced/metastatic NSCLC with EGFR exon 20 insertion mutations after progression on chemotherapy.

Amivantamab plus lazertinib prolonged overall survival vs osimertinib as first-line therapy in locally advanced or metastatic, EGFR-mutant NSCLC.

Sandip P. Patel, MD, discusses the potential role of antibody-drug conjugates in early-stage non–small cell lung cancer.

Tarlatamab was granted conditional marketing authorization in the United Kingdom for previously treated extensive-stage small cell lung cancer.

This week’s top 5 includes a snapshot of FDA approvals from December, an exclusive roundup of critical NCCN guideline updates from 2024, and more.

China's NMPA has approved taletrectinib adipate capsule for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC.

The addition of pembrolizumab to radiation did not improve survival in unresected, stage I or II non–small cell lung cancer.